BACKGROUND:Iloprost has been reported to reduce Raynaud`s phenomenon (RP) and to inhibit progression of systemic sclerosis (SSc). OBJECTIVE: The aim of our study was to compare monthly iloprost infusions with placebo in patients treated long-term. METHODS:Seventeen patients, six with RP and 11 with SSc on monthly treatment withiloprost, received either a 3-hour intravenous infusion of iloprost or an equal volume of placebo once per month for 4 months in a monocentric, randomized, placebo-controlled, double-blind study. Raynaud attacks as measured by diary entries, skin temperature, skin sclerosis, fist closure, mouth opening, and digital ulcers were recorded during the observation period. RESULTS: Whereas mouth opening improved significantly (p = 0.043) in the iloprost-treated group, RS improved in both patient groups. However, no significant differences were found in the outcome measures. CONCLUSION: Although iloprost influences the inflammatory cascade in SSc, no statistical differences were seen in our study, indicating that treatment strategies with iloprost should be modified.
RCT Entities:
BACKGROUND:Iloprost has been reported to reduce Raynaud`s phenomenon (RP) and to inhibit progression of systemic sclerosis (SSc). OBJECTIVE: The aim of our study was to compare monthly iloprost infusions with placebo in patients treated long-term. METHODS: Seventeen patients, six with RP and 11 with SSc on monthly treatment with iloprost, received either a 3-hour intravenous infusion of iloprost or an equal volume of placebo once per month for 4 months in a monocentric, randomized, placebo-controlled, double-blind study. Raynaud attacks as measured by diary entries, skin temperature, skin sclerosis, fist closure, mouth opening, and digital ulcers were recorded during the observation period. RESULTS: Whereas mouth opening improved significantly (p = 0.043) in the iloprost-treated group, RS improved in both patient groups. However, no significant differences were found in the outcome measures. CONCLUSION: Although iloprost influences the inflammatory cascade in SSc, no statistical differences were seen in our study, indicating that treatment strategies with iloprost should be modified.
Authors: S Bellando-Randone; C Bruni; G Lepri; G Fiori; F Bartoli; M L Conforti; A Moggi-Pignone; S Guiducci; D Giuggioli; M Colaci; A Spinella; C Ferri; M Matucci-Cerinic Journal: Clin Rheumatol Date: 2018-02-22 Impact factor: 2.980
Authors: Kevin Yc Su; Meghna Sharma; Hyunjun Jonathan Kim; Elizabeth Kaganov; Ian Hughes; Mohamed Hashim Abdeen; Jennifer Hwee Kwoon Ng Journal: Cochrane Database Syst Rev Date: 2021-05-17